<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40855441</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.</ArticleTitle><Pagination><StartPage>302</StartPage><MedlinePgn>302</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">302</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-025-09010-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common reason for commencement of dialysis globally. There is an urgent need for treatments to slow the loss of kidney function and prevent complications in people with ADPKD. A growing body of evidence suggests metformin may have a therapeutic role in slowing cyst progression in ADPKD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">IMPEDE-PKD is a prospective, multicentre, international, double-blind, randomized controlled trial of metformin versus placebo in adults with ADPKD. From November 2022, a total of 1174 participants will be targeted for recruitment globally, from participating kidney units in Australia, the UK, New Zealand, India, Hong Kong, South-East Asia and Europe. Following a 10-week run-in phase of extended-release metformin up-titrated to a maximum dose of 2000&#xa0;mg, participants will be randomized 1:1 to receive either metformin or placebo and followed for 2&#xa0;years. The primary outcome will be the rate of kidney function decline measured as a change in the estimated glomerular filtration rate. Secondary outcomes include other clinical markers for ADPKD progression (albuminuria, development of kidney failure), mortality, health-related QOL, pain, medication side effects, tolerability and cost-effectiveness.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">If proven effective, metformin would positively impact the well-being of people with ADPKD as a treatment option that is widely available and affordable.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">CLINICALTRIALS: gov NCT04939935. Registered on 25 June 2021.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pierre</LastName><ForeName>Kitty St</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Damanawi</LastName><ForeName>Ragada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sheffield Kidney Institute, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawley</LastName><ForeName>Carmel M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viecelli</LastName><ForeName>Andrea K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jha</LastName><ForeName>Vivekanand</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>George Institute for Global Health India, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Suetonia C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>University of Otago, Dunedin, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gesualdo</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Bari Aldo Moro, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiriwandeniya</LastName><ForeName>Charani</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velayudham</LastName><ForeName>Pushparaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergara</LastName><ForeName>Liza A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihala</LastName><ForeName>Gabor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Metro South Hospital and Health Service, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuyama</LastName><ForeName>Misa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>Peta-Ann Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallett</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-8752-2551</Identifier><AffiliationInfo><Affiliation>The University of Queensland, Brisbane, Australia. andrew.mallett@health.qld.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Townsville University Hospital, Townsville Hospital and Health Service, Townsville, Australia. andrew.mallett@health.qld.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Dentistry, James Cook University, Townsville, Australia. andrew.mallett@health.qld.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>IMPEDE-PKD Global&#xa0;Steering Committee&#xa0;(see Appendix)</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04939935</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MRF1199853</GrantID><Agency>Medical Research Future Fund</Agency><Country/></Grant><Grant><GrantID>APP1092957</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><GrantID>NIHR156614</GrantID><Agency>Efficacy and Mechanism Evaluation Programme</Agency><Country/></Grant><Grant><GrantID>23/093/A</GrantID><Agency>Health Research Council of New Zealand</Agency><Country/></Grant><Grant><GrantID>IIRP-2023-4050</GrantID><Agency>Indian Council of Medical Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016891" MajorTopicYN="Y">Polycystic Kidney, Autosomal Dominant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="Y">Kidney</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autosomal dominant polycystic kidney disease</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate {24}: Ethics approval for the IMPEDE-PKD trial was obtained in Queensland, Australia, from Metro South Hospital and Health Service Human Research and Ethics Committee (approval reference HREC/2021/QMS/70436). The study has received local governance approvals at each of the participating sites. Each participating jurisdiction will ensure relevant regulatory and ethical approvals are received prior to the trial beginning in that country. Consent for publication: Consent for publication is not applicable since there are no identifying images or other personal or clinical details of participants presented. A model participant information sheet and consent form are provided. Competing interests {28}: AJM has previously received research funding from Sanofi-Genzyme, been a member of a Medical Advisory Board for Otsuka Australia, and been clinical trial local site Principal Investigator for Reata, Sanofi-Genzyme and Dicerna. AJM is supported by a Queensland Government Advancing Clinical Research Fellowship. DWJ has received consultancy fees, research grants, speaker&#x2019;s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca, Bayer and AWAK, speaker&#x2019;s honoraria from ONO and Boehringer Ingelheim &amp; Lilly, and travel sponsorships from Ono and Amgen. VJ reports consulting fee/honoraria from Bayer, Astra Zeneca, Boehringer Ingelheim, Biocryst, Vera, Visterra, Otsuka, Novartis, Astra Zeneca, Chinook, Biocryst and Alpine under the policy of all payments going to the organization. The other coauthors declare no relevant conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40855441</ArticleId><ArticleId IdType="pmc">PMC12376749</ArticleId><ArticleId IdType="doi">10.1186/s13063-025-09010-6</ArticleId><ArticleId IdType="pii">10.1186/s13063-025-09010-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torres VE, et al. Kdigo 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025;107(2):234&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">39848746</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812475</ArticleId><ArticleId IdType="pubmed">19455193</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760207</ArticleId><ArticleId IdType="pubmed">23121377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613459</ArticleId><ArticleId IdType="pubmed">26475449</ArticleId></ArticleIdList></Reference><Reference><Citation> De&#xa0;Broe, Marc&#xa0;E., F. Kajbaf, and J.-D. Lalau, <i>Renoprotective Effects of Metformin.</i> Nephron, 2018;&#xa0;138(4): p. 261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter M, Germino GG. Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology. J Lab Clin Med. 2003;141(2):91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran S, et al. Nephroprotective Effects of Metformin in Diabetic Nephropathy: METFORMIN AND ITS NEPHROPROTECTIVE EFFECTS. J Cell Physiol. 2017;232(4):731&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27627216</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor-Soler NM, et al. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Renal Physiol. 2022;322(1):F27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">34806449</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiken C, et al. An Update to the Article &#x201c;Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.&#x201d; Diabetes Ther. 2021;12(11):2813&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519970</ArticleId><ArticleId IdType="pubmed">34596878</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinstatler L, et al. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements: The National Health and Nutrition Examination Survey, 1999&#x2013;2006. Diabetes Care. 2012;35(2):327&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263877</ArticleId><ArticleId IdType="pubmed">22179958</ArticleId></ArticleIdList></Reference><Reference><Citation> Salpeter, S.R., et al., <i>Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.</i> Cochrane library. 2010(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138050</ArticleId><ArticleId IdType="pubmed">20393934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorohan BM, et al. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2019;20(1):276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651959</ArticleId><ArticleId IdType="pubmed">31337351</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatasubramanian V, et al. Metformin versus standard of care in patients with autosomal dominant polycystic kidney disease &#x2013; a randomized control trial. Indian J Nephrol. 2024. 10.25259/IJN_100_2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12065615</ArticleId><ArticleId IdType="pubmed">40352872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasari A, et al. SUN-200 role of metformin in ADPKD patients. Kidney Int. 2019;4(7):S242.</Citation></Reference><Reference><Citation>Roy Chaudhary A, et al. POS-494 an open label randomized controlled study to evaluate the role of Metformin to retard the progression of ADPKD. Kidney Int. 2021;6(4):S213&#x2013;4.</Citation></Reference><Reference><Citation>Perrone RD, et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021;100(3):684&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801184</ArticleId><ArticleId IdType="pubmed">34186056</ArticleId></ArticleIdList></Reference><Reference><Citation> Brosnahan, G.M., et al., <i>Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.</i> Am J Kidney Dis, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837717</ArticleId><ArticleId IdType="pubmed">34391872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangan GK, et al. KHA-cari guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016;21(8):705&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">26511892</ArticleId></ArticleIdList></Reference><Reference><Citation>Blonde L, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15119994</ArticleId></ArticleIdList></Reference><Reference><Citation> Kidney Health Australia, <i>Acute Kidney Injury Sick Day Plan factsheet</i>. 2017.</Citation></Reference><Reference><Citation>Schrier RW, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4343258</ArticleId><ArticleId IdType="pubmed">25399733</ArticleId></ArticleIdList></Reference><Reference><Citation>Takiar V, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108(6):2462&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038735</ArticleId><ArticleId IdType="pubmed">21262823</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DW, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012;197(4):222&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">22900871</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation> Otsuka Pharmaceutical Developement &amp; Commercialization Inc, <i>Autosomal Dominant Polycystic Kidney Disease Pain and Discomfort Scale (ADPKD-PDS)</i>. 2016, Mapi Research Trust. .</Citation></Reference><Reference><Citation>Svedlund J, Sj&#xf6;din I, Dotevall G. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123181</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres VE, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">29105594</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, et al. Gfr slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6727261</ArticleId><ArticleId IdType="pubmed">31292197</ArticleId></ArticleIdList></Reference><Reference><Citation> Inc., O.P.D.C. <i>Autosomal Dominant Polycystic Kidney Disease Pain and Discomfort Scale (ADPKD-PDS)</i>. 2016; Available from: https://eprovide.mapi-trust.org/instruments/autosomal-dominant-polycystic-kidney-disease-pain-and-discomfort-scale.</Citation></Reference><Reference><Citation> Expert Panel on Detection, E.T.o.H.B.C.i.A., <i>Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).</i> JAMA, 2001. 285(19): p. 2486&#x2013;2497.</Citation><ArticleIdList><ArticleId IdType="pubmed">11368702</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, et al. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208&#x2013;103208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Loudon K, et al. The precis-2 tool: designing trials that are fit for purpose. BMJ. 2015;350(may08 1):h2147&#x2013;h2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">25956159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, et al. Establishing a core outcome set for autosomal dominant polycystic kidney disease: report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) consensus workshop. Am J Kidney Dis. 2021;77(2):255&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">32771648</ArticleId></ArticleIdList></Reference><Reference><Citation> U.S. National Library or Medicine. <i>A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD). Identifier: NCT03523728</i>. 2021 23/12/21]; Available from: https://clinicaltrials.gov/ct2/show/NCT03523728.</Citation></Reference><Reference><Citation> U.S National Library of Medicine. <i>A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON). Identifier: NCT03918447</i>. 2019 23/12/21]; Available from: https://clinicaltrials.gov/ct2/show/NCT03918447.</Citation></Reference><Reference><Citation> Rangan, G.K., et al., <i>Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.</i> N Engl J Med Evidence, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">38319283</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>